Venus Remedies Limited
VENUSREM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,789.35.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%16.8%
- ✓Low debt (D/E < 0.5)0.02x
- ✓Positive free cash flow
- ✓Revenue growth > 10%33%
- ✓Earnings growing126%
- ✓Net margin ≥ 10%13.4%
- ✓Current ratio > 1.52.44
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 9.19
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Trading near its 52-week high.
- •Financially solid — Altman Z 9.19.
Opportunities
- •Earnings growing (126% YoY).
- •Revenue growing (33% YoY).
- •Trading in our value buy zone versus sector peers.
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurol
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.